Novelix Pharmaceuticals (BOM:536565) Beneish M-Score: 6.10 (As of Jul. 04, 2026)


BOM:536565 Novelix Pharmaceuticals Ltd BOM:536565
68 GF Score
Price ₹77.97
GF Value ₹144.17
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Novelix Pharmaceuticals Beneish M-Score?

Novelix Pharmaceuticals BOM:536565 -0.80% 68 Beneish M-Score is 6.10 as of Jul. 04, 2026. GuruFocus rates BOM:536565 with a GF Score™ of 68/100 and a GF Value™ of ₹144.17 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 112 Medical Distribution companies, Novelix Pharmaceuticals ranks worse than 98.21% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 6.1 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Novelix Pharmaceuticals's Beneish M-Score or its related term are showing as below:

BOM:536565' s Beneish M-Score Range Over the Past 10 Years
Min: -50.67   Med: -2.38   Max: 6.1
Current: 6.1

During the past 13 years, the highest Beneish M-Score of Novelix Pharmaceuticals was 6.10. The lowest was -50.67. And the median was -2.38.


Novelix Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Novelix Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelix Pharmaceuticals Beneish M-Score Chart

Novelix Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.05 -3.04 -1.19 -50.67 6.10

Novelix Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.67 0.00 0.00 0.00 6.10

BOM:536565 vs MCK, CAH, COR: Beneish M-Score Comparison

For the Medical Distribution subindustry, Novelix Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novelix Pharmaceuticals Beneish M-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Novelix Pharmaceuticals's Beneish M-Score falls into.


BOM:536565
68GF Score
Novelix Pharmaceuticals Ltd BOM:536565
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novelix Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Novelix Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8806+0.528 * 0.8818+0.404 * 11.7421+0.892 * 4.3071+0.115 * 2.3309
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.269907-0.327 * 1.3987
=6.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹688 Mil.
Revenue was ₹1,323 Mil.
Gross Profit was ₹56 Mil.
Total Current Assets was ₹889 Mil.
Total Assets was ₹924 Mil.
Property, Plant and Equipment(Net PPE) was ₹15 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹416 Mil.
Long-Term Debt & Capital Lease Obligation was ₹43 Mil.
Net Income was ₹26 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹-224 Mil.
Total Receivables was ₹181 Mil.
Revenue was ₹307 Mil.
Gross Profit was ₹11 Mil.
Total Current Assets was ₹269 Mil.
Total Assets was ₹272 Mil.
Property, Plant and Equipment(Net PPE) was ₹2 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹0 Mil.
Selling, General, & Admin. Expense(SGA) was ₹4 Mil.
Total Current Liabilities was ₹97 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(687.923 / 1323.062) / (181.369 / 307.185)
=0.519948 / 0.590423
=0.8806

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(11.448 / 307.185) / (55.914 / 1323.062)
=0.037267 / 0.042261
=0.8818

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (889.112 + 15.218) / 924.233) / (1 - (269.329 + 2.237) / 272.065)
=0.021535 / 0.001834
=11.7421

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1323.062 / 307.185
=4.3071

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.38 / (0.38 + 2.237)) / (1.011 / (1.011 + 15.218))
=0.145204 / 0.062296
=2.3309

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 1323.062) / (3.764 / 307.185)
=0 / 0.012253
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((43.219 + 416.13) / 924.233) / ((0 + 96.672) / 272.065)
=0.497006 / 0.355327
=1.3987

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(25.566 - 0 - -223.891) / 924.233
=0.269907

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Novelix Pharmaceuticals has a M-score of 6.10 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 6.10 mean?
Novelix Pharmaceuticals (BOM:536565) has a Beneish M-Score of 6.10 as of Jul. 04, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Novelix Pharmaceuticals and its competitors. According to the industry distribution chart, Novelix Pharmaceuticals ranks #110 out of 112 companies in the Medical Distribution industry, placing it in the top 98.2%.
Is Novelix Pharmaceuticals' Beneish M-Score too high?
Novelix Pharmaceuticals' current Beneish M-Score is 6.10. Based on the distribution chart, Novelix Pharmaceuticals ranks #110 out of 112 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Novelix Pharmaceuticals has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' Beneish M-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Novelix Pharmaceuticals ranks #110 out of 112 companies for Beneish M-Score. This places Novelix Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Distribution company?
A good Beneish M-Score depends on the Medical Distribution industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Novelix Pharmaceuticals and its competitors. Novelix Pharmaceuticals's current Beneish M-Score is 6.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Novelix Pharmaceuticals (BOM:536565) is currently considered Possible Value Trap. The stock's GF Value™ is ₹144.17, compared to a current price of ₹77.97 — trading 45.9% below its estimated fair value. The current Beneish M-Score is 6.10. Novelix Pharmaceuticals' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current Beneish M-Score is 6.10 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novelix Pharmaceuticals (BOM:536565) Overvalued in 2026?

Based on GuruFocus' analysis, Novelix Pharmaceuticals stock appears to be undervalued. The current stock price of ₹77.97 is trading 45.9% below its estimated GF Value™ of ₹144.17. GuruFocus considers Novelix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for BOM:536565:

  • Beneish M-Score: 6.10
  • GF Value™: ₹144.17 vs. price of ₹77.97 (45.9% below fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the BOM:536565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novelix Pharmaceuticals Business Description

Address Lingapur LA Builders, Amrutha Estates, 6th floor, House no. 3-6-237/610, Himayath nagar, Hyderabad, TG, IND, 500029
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
68GF Score

Get the complete analysis for BOM:536565

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹77.97
Price
₹144.17
GF Value